KIT and acute myeloid leukemia: The other class III receptor tyrosine kinase, c-KIT, which also plays a pivotal role in AML, is expressed by myeloblasts in about 60% to 80% of patients: Therefore, next to the described FLT3 aberrations c-KIT harbors the most frequently observed activating RTK mutations in AML with an overall incidence of 17%.